By Nicholas G. Miller
Zimmer Biomet now expects to buy back up to $1 billion of its stock during the fiscal year, up $250 million from its previous expectation.
The buybacks will be made under the company's $1.5 billion share repurchase authorization, which it hasn't modified.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
May 12, 2026 07:40 ET (11:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.